Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 149
Filter
1.
Value Health ; 24(6): 789-794, 2021 06.
Article in English | MEDLINE | ID: mdl-34119076

ABSTRACT

OBJECTIVES: The Institute for Clinical and Economic Review (ICER) is an independent organization that reviews drugs and devices with a focus on emerging agents. As part of their evaluation, ICER estimates value-based prices (VBP) at $50 000 to $150 000 per quality-adjusted life-year (QALY) gained thresholds. We compared actual estimated net prices to ICER-estimated VBPs. METHODS: We reviewed ICER final evidence reports from November 2007 to October 2020. List prices were combined with average discounts obtained from SSR Health to estimate net prices. If a drug had been evaluated more than once for the same indication, only the more recent VBP was included. RESULTS: A total of 34 ICER reports provided unique VBPs for 102 drugs. The net price of 81% of drugs exceeded the $100 000 per QALY VBP and 71% exceeded the $150 000 per QALY VBP. The median change in net price needed to reach the $150 000 per QALY VBP was a 36% reduction. The median decrease in net price needed was highest for drugs targeting rare inherited disorders (n = 15; 62%) and lowest for cardiometabolic disorders (n = 6; 162% price increase). The reduction in net prices needed to reach ICER-estimated VBPs was higher for drugs evaluated for the first approved indication, rare diseases, less competitive markets, and if the drug approval occurred before the ICER report became available. CONCLUSION: Net prices are often above VBPs estimated by ICER. Although gaining awareness among decision makers, the long-term impact of ICER evaluations on pricing and access to new drugs continues to evolve.


Subject(s)
Drug Costs , Drug Utilization Review/economics , Technology Assessment, Biomedical/economics , Value-Based Purchasing/economics , Cost-Benefit Analysis , Decision Support Techniques , Humans , Models, Economic , Quality-Adjusted Life Years , Retrospective Studies
2.
J Oncol Pharm Pract ; 27(3): 635-643, 2021 Apr.
Article in English | MEDLINE | ID: mdl-32539663

ABSTRACT

INTRODUCTION: Cancer drug therapy costs continue to rise and threaten the sustainability of Canada's public healthcare system. Previous studies have calculated potential savings utilizing different dosing regimens of cancer treatments. Our objectives were to determine the financial impact of drug wastage and to explore cost-effective dosing regimens for pembrolizumab. METHODS: This was a retrospective study reviewing data for non-small cell lung cancer and melanoma patients at all six BC Cancer Regional Centres during fiscal years 2017 and 2018. Pembrolizumab waste amounts recorded in pharmacy wastage logs were totalled. Estimates of the number of vials used were compared between vial sharing and non-vial sharing practices to determine the cost differences. Costs for dosing regimens used during fiscal years 2017 and 2018 were compared to 2 mg/kg weight-based dosing (to a maximum of 200 mg), 2 mg/kg dosing rounding down within 5% and 10%, and flat dosing of 200 mg. RESULTS: There were a total of 202 non-small cell lung cancer and 182 melanoma patients with 2948 doses dispensed. Documented wastage was valued at $1,829,047.44 (8.65%) and across all six centres, vial sharing could reduce costs by $3,207,600.00 using the 100 mg vials. Compared to fiscal years 2017 and 2018, 2 mg/kg dosing (to a maximum of 200 mg) was the most cost-effective, decreasing costs by $222,719.20; flat dosing of 200 mg was the most expensive, increasing costs by $6,625,260.40. CONCLUSIONS: Having smaller vial sizes, practicing vial sharing, and using weight-based dosing all improve cost savings. Further investigations on the allocation of resources to optimize drug use and minimize wastage are needed.


Subject(s)
Antibodies, Monoclonal, Humanized/administration & dosage , Antineoplastic Agents, Immunological/administration & dosage , Cost Savings/statistics & numerical data , Drug Costs/statistics & numerical data , Drug Utilization Review/statistics & numerical data , Antibodies, Monoclonal, Humanized/economics , Antineoplastic Agents, Immunological/economics , British Columbia/epidemiology , Carcinoma, Non-Small-Cell Lung/drug therapy , Carcinoma, Non-Small-Cell Lung/economics , Carcinoma, Non-Small-Cell Lung/epidemiology , Cost Savings/methods , Cost-Benefit Analysis/methods , Cost-Benefit Analysis/statistics & numerical data , Dose-Response Relationship, Drug , Drug Utilization Review/economics , Drug Utilization Review/methods , Female , Humans , Lung Neoplasms/drug therapy , Lung Neoplasms/economics , Lung Neoplasms/epidemiology , Male , Melanoma/drug therapy , Melanoma/economics , Melanoma/epidemiology , Retrospective Studies , Skin Neoplasms/drug therapy , Skin Neoplasms/economics , Skin Neoplasms/epidemiology
3.
Am J Health Syst Pharm ; 77(15): 1243-1248, 2020 07 23.
Article in English | MEDLINE | ID: mdl-32620961

ABSTRACT

PURPOSE: To design and implement a chemotherapy stewardship process to optimize the location of chemotherapy administration in an effort to decrease the number of inappropriate inpatient anticancer regimen administrations and decrease institutional costs associated with inpatient administration. SUMMARY: As the costs of anticancer agents continue to rise, it is crucial that multidisciplinary efforts are aimed at managing anticancer medication utilization; this is especially important for high-cost medications, medications whose use requires increased monitoring due to safety concerns, and medications that do not exert effects quickly and, as such, can be more appropriately administered in the outpatient setting. It is imperative that pharmacists play a role in managing chemotherapy medication utilization, as pharmacists provide expertise in formulary management, a vast knowledge of financial impact and reimbursement processes, and clinical knowledge that can help predict the expected effectiveness and adverse effects of each anticancer regimen. Our institution sought to develop and implement a multidisciplinary chemotherapy stewardship program targeting the optimization of site of anticancer agent administration with a goal of decreasing both cost and inappropriate utilization of high-cost, high-risk anticancer agents. CONCLUSION: Implementation of a chemotherapy stewardship service may decrease the number of inappropriate inpatient anticancer regimen administrations and decrease inpatient resource use, thereby decreasing costs to institutions. The concept of a chemotherapy stewardship process was well received by multidisciplinary healthcare colleagues, and a collaborative approach should be used to design and implement such processes.


Subject(s)
Antineoplastic Agents/standards , Cost-Benefit Analysis/standards , Drug Utilization Review/standards , Pharmacists/standards , Pharmacy Service, Hospital/standards , Antineoplastic Agents/economics , Cost-Benefit Analysis/economics , Drug Utilization Review/economics , Humans , Pharmacists/economics , Pharmacy Service, Hospital/economics
5.
Drugs Aging ; 37(5): 393-398, 2020 05.
Article in English | MEDLINE | ID: mdl-32227290

ABSTRACT

BACKGROUND: Temporal changes in the dispensing of glucose-lowering drugs (GLD) and their associated costs among elderly populations is unclear. This information is especially relevant to countries in which medications are partly or fully government subsidized. OBJECTIVE: Our objective was to estimate the trends in prevalence, incidence and costs associated with GLD dispensed to older Australians. METHODS: We analysed Pharmaceutical Benefits Scheme data for 76,906 people aged ≥ 65 years dispensed diabetes medications over the period 2013-2016. RESULTS: Older males were dispensed more GLD than were older females, with the marginal difference increasing from 3.2% in 2013 (age-sex adjusted incidence rate ratio [aIRR] 1.032; 95% confidence interval [CI] 1.024-1.041; p < 0.001) to 3.9% in 2016 (aIRR 1.039; 95% CI 1.030-1.047; p < 0.001). The number of GLD dispensed per person was consistently lower in those aged ≥ 75 years than in those aged 65-74 years, with the gap widening over the years. More patients were initiated with sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors over the study period, at the expense of older GLD. The proportion of users and attributed costs associated with the use of metformin, sulfonylureas, α-glucosidase inhibitors and thiazolidinediones decreased over time. The total subsidized costs of GLD is forecast to increase to $A395 million by 2020. CONCLUSIONS: The treatment landscape for diabetes in Australia is undergoing dynamic change. More patients were initiated with the newer but costlier GLD over the study period.


Subject(s)
Diabetes Mellitus, Type 2/drug therapy , Drug Costs , Drug Utilization Review/trends , Hypoglycemic Agents/therapeutic use , Insurance Claim Review/trends , Aged , Australia/epidemiology , Blood Glucose/analysis , Databases, Factual , Diabetes Mellitus, Type 2/epidemiology , Drug Utilization Review/economics , Female , Humans , Hypoglycemic Agents/administration & dosage , Hypoglycemic Agents/economics , Insurance Claim Review/statistics & numerical data , Male
6.
Am J Health Syst Pharm ; 76(23): 1934-1943, 2019 Nov 13.
Article in English | MEDLINE | ID: mdl-31628792

ABSTRACT

PURPOSE: Many medications that were marketed prior to 1962 but lack Food and Drug Administration (FDA) approval are prescribed in the United States. Usage patterns of these "unapproved medications" are poorly elucidated, which is concerning due to potential lack of data on safety and efficacy. The purpose of this project was to characterize purchases of unapproved medications within the Veterans Health Administration (VHA) by type, frequency, and cost. METHODS: VHA purchasing databases were used to create a list of all products with National Drug Codes (NDCs) purchased nationwide in fiscal year 2016 (FY16). This list was compared to FDA databases to identify unapproved prescription medications. For each identified combination of active pharmaceutical ingredient (API) and route of administration ("API/route combination"), numbers of packages purchased and associated costs were added. RESULTS: VHA pharmacy purchasing records contained 3,299 unapproved products with NDCs in FY16. After excluding equipment, nutrition products, compounding ingredients, nonmedication products, and duplicate NDCs, there were 600 unique NDCs associated with 130 distinct API/route combinations. The most commonly acquired product was prescription sodium fluoride dental paste (350,775 packages). The greatest pharmaceutical expenditure was for sodium hyaluronate injection ($24.5 million). Unapproved products accounted for less than 1% of overall VHA pharmacy purchasing in FY16. CONCLUSION: VHA purchased many unapproved prescription products in FY16 but is taking action to address use of such products in consideration of safety and efficacy data and available alternatives.


Subject(s)
Drug Approval , Drug Utilization Review/statistics & numerical data , Pharmacies/statistics & numerical data , Prescription Drugs/economics , United States Department of Veterans Affairs/statistics & numerical data , Drug Utilization Review/economics , Drug Utilization Review/legislation & jurisprudence , Humans , Pharmacies/economics , Pharmacies/legislation & jurisprudence , United States , United States Department of Veterans Affairs/economics , United States Department of Veterans Affairs/legislation & jurisprudence , United States Food and Drug Administration/legislation & jurisprudence
7.
Poult Sci ; 98(12): 6644-6658, 2019 Dec 01.
Article in English | MEDLINE | ID: mdl-31557295

ABSTRACT

Antimicrobial resistance is a global threat for both human and animal health. One of the main drivers of antimicrobial resistance is inappropriate antimicrobial use in livestock production. The aim of this study was to examine the technical and economic impact of tailor-made interventions, aimed at reducing antimicrobial use in broiler production. Historical (i.e., before intervention) and observational (i.e., after intervention) data were collected at 20 broiler farms. Results indicate that average daily gain and mortality generally increased after intervention, whereas feed conversion and antimicrobial use decreased. Economic performance after interventions was generally higher than before the interventions. Sensitivity analyses on price changes confirm the robustness of the findings.


Subject(s)
Animal Husbandry/methods , Anti-Infective Agents/therapeutic use , Chickens , Drug Utilization Review/statistics & numerical data , Animal Husbandry/economics , Animals , Drug Utilization Review/economics , Europe , Health Planning/economics , Health Planning/statistics & numerical data , Program Evaluation
8.
Int J Clin Pharm ; 41(4): 963-971, 2019 Aug.
Article in English | MEDLINE | ID: mdl-31209718

ABSTRACT

Background Drug-related problems (DRP) following hospital discharge may cause morbidity, mortality and hospital re-admissions. It is unclear whether a clinical medication review (CMR) and counseling at discharge is a cost-effective method to reduce DRP. Objective To assess the effect of a CMR on health care utilization and to investigate whether CMR is a cost-effective method to reduce DRP in older polypharmacy patients discharged from hospital. Setting 24 community pharmacies in the Netherlands. Method A cluster-randomized controlled trial with an economic evaluation. Community pharmacies were randomized to those providing a CMR, counseling and follow-up at discharge and those providing usual care. Main outcome measures Change in the number of DRP after 1 year of follow-up and costs of health care utilization during follow-up. In 216 patients the use of health care was prospectively assessed. Missing data on effects and costs were imputed using multiple imputation techniques. Bootstrapping techniques were used to estimate the uncertainty around the differences in costs and incremental cost-effectiveness ratios. Results CMR resulted in a small reduction of DRP. The proportion of patients readmitted to the hospital during 6 months of follow-up was significantly higher in the intervention group than in the control group (46.4 vs. 20.9%; p < 0.05). Health care costs were higher in the intervention group, although not statistically significant. The costs of reducing one DRP by a CMR amounted to €8270. Conclusion A CMR in vulnerable older patients at hospital discharge led to a small reduction in DRP. Because of a significantly higher use of health care and higher number of re-hospitalisations post CMR, the present study data indicate that performing the intervention in this patient population is not cost-effective.


Subject(s)
Cost-Benefit Analysis , Drug Utilization Review/economics , Drug-Related Side Effects and Adverse Reactions/prevention & control , Patient Acceptance of Health Care/statistics & numerical data , Patient Discharge/statistics & numerical data , Aged , Community Pharmacy Services/economics , Drug Utilization Review/statistics & numerical data , Female , Health Care Costs/statistics & numerical data , Humans , Male , Netherlands , Patient Readmission/statistics & numerical data
9.
PLoS One ; 13(12): e0209383, 2018.
Article in English | MEDLINE | ID: mdl-30566426

ABSTRACT

BACKGROUND: While the rise in opioid analgesic prescribing and overdose deaths was multifactorial, financial relationships between opioid drug manufacturers and physicians may be one important factor. METHODS: Using national data from 2013 to 2015, we conducted a retrospective cohort study linking the Open Payments database and Medicare Part D drug utilization data. We created two cohorts of physicians, those receiving opioid-related payments in 2014 and 2015, but not in 2013, and those receiving opioid-related payments in 2015 but not in 2013 and 2014. Our main outcome measures were expenditures on filled prescriptions, daily doses filled, and expenditures per daily dose. For each cohort, we created a comparison group that did not receive an opioid-related payment in any year and was matched on state, specialty, and baseline opioid expenditures. We used a difference-in-differences analysis with linear generalized estimating equations regression models. RESULTS: We identified 6,322 physicians who received opioid-related payments in 2014 and 2015, but not in 2013; they received a mean total of $251. Relative to comparison group physicians, they had a significantly larger increase in mean opioid expenditures ($6,171; 95% CI: 4,997 to 7,346), daily doses dispensed (1,574; 95%CI: 1,330 to 1,818) and mean expenditures per daily dose ($0.38; 95% CI: 0.29 to 0.47). We identified 8,669 physicians who received opioid-related payments in 2015, but not in 2013 or 2014; they received a mean total of $40. Relative to comparison physicians, they also had a larger increase in mean opioid expenditures ($1,031; 95% CI: 603 to 1,460), daily doses dispensed (557; 95% CI: 417 to 697), and expenditures per daily dose ($0.06; 95% CI: 0.002 to 0.13). CONCLUSIONS: Our findings add to the growing public policy concern that payments from opioid drug manufacturers can influence physician prescribing. Interventions are needed to reduce such promotional activities or to mitigate their influence.


Subject(s)
Analgesics, Opioid , Drug Industry/economics , Drug Utilization Review/statistics & numerical data , Health Expenditures/statistics & numerical data , Practice Patterns, Physicians'/statistics & numerical data , Drug Costs/statistics & numerical data , Drug Industry/ethics , Drug Prescriptions/economics , Drug Prescriptions/statistics & numerical data , Drug Utilization Review/economics , Gift Giving/ethics , Humans , Medicare Part D/economics , Medicare Part D/statistics & numerical data , Practice Patterns, Physicians'/economics , Practice Patterns, Physicians'/ethics , Public Policy/economics , Retrospective Studies , United States
10.
J Oncol Pharm Pract ; 24(8): 604-608, 2018 Dec.
Article in English | MEDLINE | ID: mdl-28782407

ABSTRACT

PURPOSE: Pegfilgrastim is indicated to reduce the risk of febrile neutropenia. As a cost-savings initiative, Pegfilgrastim Process Guidelines were developed and implemented at a large, academic teaching institution to improve appropriate use of pegfilgrastim and to decrease costs of outpatient infusion center administration by deferring doses to home self-administration for eligible patients. METHODS: A retrospective medical record review was conducted post-implementation of the Pegfilgrastim Process Guideline to evaluate the use of pegfilgrastim and to assess the safety and efficacy of transferring pegfilgrastim orders from outpatient infusion center to home administration for eligible patients. RESULTS: Fifty-nine patients were included in the study, with 35 patients receiving pegfilgrastim in the outpatient infusion center, 13 patients self-injecting at home, and 11 patients receiving doses in both settings. The total wholesale cost avoidance for pegfilgrastim orders transferred to self-administration at home during this time period totaled $205,163. The revenue from outpatient prescriptions of pegfilgrastim totaled $291,111.93. The percentage of febrile neutropenia admissions was 11.4%, 0%, and 9.1% in the outpatient infusion, home, and outpatient/home group, respectively. CONCLUSION: Implementation of the Pegfilgrastim Process Guidelines demonstrated decreased total pegfilgrastim orders to be dispensed by the infusion center and a cost avoidance of $205,163 in four months without any perceivable changes in patient outcomes. This represents a significant cost-savings opportunity.


Subject(s)
Academic Medical Centers/methods , Cost Savings/methods , Drug Utilization Review/methods , Filgrastim/therapeutic use , Neutropenia/drug therapy , Polyethylene Glycols/therapeutic use , Academic Medical Centers/economics , Academic Medical Centers/trends , Adult , Cost Savings/trends , Cost-Benefit Analysis/methods , Cost-Benefit Analysis/trends , Drug Utilization Review/economics , Drug Utilization Review/trends , Female , Filgrastim/economics , Humans , Male , Middle Aged , Neutropenia/economics , Polyethylene Glycols/economics , Retrospective Studies
11.
Rheumatol Int ; 38(4): 663-668, 2018 Apr.
Article in English | MEDLINE | ID: mdl-29204683

ABSTRACT

To analyze the biologics usage and expenditure for the treatment of patients with rheumatoid arthritis (RA) in each prefecture throughout Japan using the national open database, the Ministry of Health, Labour and Welfare of Japan disclosed; in Oct 2016, the data of the top 30 most-frequently prescribed drugs during a 1-year period from April 2014 to March 2015 in each prefecture in Japan, along with the patients' age and sex. Seldom-used drugs were excluded. We picked up only biologics for the present study. The total expenditure on biologics used in each prefecture was correlated with the population thereof. However, there was a big difference, up to ~ twofold, in the average expenditure used for an RA patient: highest in Toyama and lowest in Wakayama. There was also a big difference, ~ 4.5-fold, in the number of rheumatologists/1000 RA patients, highest in Kyoto and lowest in Aomori. The average expenditure used for an RA patient was correlated with the number of rheumatologists in the western part of Japan. Etanercept seemed to be used most frequently to Japanese RA patients followed closely by infliximab. Abatacept was used more frequently to the elderly than other biologics. There was a big difference in the number of rheumatologists and expenditure on biologics for the treatment of an RA patient among prefectures in fiscal 2014. Factors that brought this unevenness need to be scrutinized for universal implementation of good RA care throughout Japan, where there are uniform health insurance system and free access to rheumatologists.


Subject(s)
Administrative Claims, Healthcare , Antirheumatic Agents/economics , Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/drug therapy , Arthritis, Rheumatoid/economics , Biological Products/economics , Biological Products/therapeutic use , Databases, Factual , Drug Costs/trends , Health Expenditures/trends , Practice Patterns, Physicians' , Rheumatologists , Adolescent , Adult , Aged , Aged, 80 and over , Antirheumatic Agents/adverse effects , Arthritis, Rheumatoid/diagnosis , Biological Products/adverse effects , Child , Child, Preschool , Cost-Benefit Analysis , Drug Utilization Review/economics , Drug Utilization Review/trends , Female , Healthcare Disparities/economics , Healthcare Disparities/trends , Humans , Infant , Infant, Newborn , Japan , Male , Middle Aged , Practice Patterns, Physicians'/economics , Practice Patterns, Physicians'/trends , Rheumatologists/economics , Rheumatologists/trends , Time Factors , Treatment Outcome , Young Adult
12.
Med Care Res Rev ; 75(2): 153-174, 2018 04.
Article in English | MEDLINE | ID: mdl-29148319

ABSTRACT

Medicare Part D was associated with reduced hospitalizations, yet little is known whether these effects varied across patients and how Part D was associated with length of stay and inpatient expenditures. We used Medicare claims and the Medicare Current Beneficiary Survey from 2002 to 2010 and an instrumental variables approach. Gaining drug insurance through Part D was associated with a statistically significant 8.0% reduction in likelihood of admission across conditions examined. Reductions were generally greater for younger, healthier, and male individuals. Across all conditions, mean length of stay decreased by 3.2% from a baseline of 5.1 days. Part D was associated with a 3.5% reduction in expenditures per admission, reflecting a decrease of $844 from a mean charge of $24,124 per admission prior to Part D. Thus, Part D was associated with statistically and clinically significant reductions in the probability of admission and length of stay for several common conditions.


Subject(s)
Drug Utilization Review/economics , Drug Utilization Review/statistics & numerical data , Health Expenditures/statistics & numerical data , Insurance Coverage/economics , Medicare Part D/economics , Medicare Part D/statistics & numerical data , Prescription Drugs/economics , Aged , Aged, 80 and over , Female , Humans , Insurance Coverage/statistics & numerical data , Male , United States
13.
Int J Clin Pharm ; 39(4): 750-758, 2017 Aug.
Article in English | MEDLINE | ID: mdl-28434119

ABSTRACT

Background Medication review with follow-up (MRF) is a professional pharmacy service proven to be cost-effective. Its broader implementation is limited, mainly due to the lack of evidence-based implementation programs that include economic and financial analysis. Objective To analyse the costs and estimate the price of providing and implementing MRF. Setting Community pharmacy in Spain. Method Elderly patients using poly-pharmacy received a community pharmacist-led MRF for 6 months. The cost analysis was based on the time-driven activity based costing model and included the provider costs, initial investment costs and maintenance expenses. The service price was estimated using the labour costs, costs associated with service provision, potential number of patients receiving the service and mark-up. Main outcome measures Costs and potential price of MRF. Results A mean time of 404.4 (SD 232.2) was spent on service provision and was extrapolated to annual costs. Service provider cost per patient ranged from €196 (SD 90.5) to €310 (SD 164.4). The mean initial investment per pharmacy was €4594 and the mean annual maintenance costs €3,068. Largest items contributing to cost were initial staff training, continuing education and renting of the patient counselling area. The potential service price ranged from €237 to €628 per patient a year. Conclusion Time spent by the service provider accounted for 75-95% of the final cost, followed by initial investment costs and maintenance costs. Remuneration for professional pharmacy services provision must cover service costs and appropriate profit, allowing for their long-term sustainability.


Subject(s)
Community Pharmacy Services/economics , Cost-Benefit Analysis/methods , Drug Utilization Review/economics , Drug Utilization Review/methods , Pharmacists/economics , Professional Role , Aged , Aged, 80 and over , Female , Follow-Up Studies , Humans , Male , Spain/epidemiology
14.
Health Econ ; 26(12): e160-e178, 2017 12.
Article in English | MEDLINE | ID: mdl-28233420

ABSTRACT

I study the effect of prescription drug essential health benefits (EHB) requirements from the Affordable Care Act on prescription drug formularies of health insurance marketplace plans. The EHB regulates the number of drugs covered but leaves other dimensions (cost sharing and utilization management) of the formulary unregulated. Using data on almost all formularies in the country, I demonstrate that requiring insurers to cover one additional drug adds 0.22 drugs (3.3%) to the average formulary, mostly owing to firms increasing the number of drugs covered to comply with the EHB requirement. The EHB requirement also increases the probability that a drug is subject to utilization management and is assigned to a higher (more costly) formulary tier. My results suggest that newly covered drugs are 22.3 percentage points more likely to be subject to utilization management, compared to 36.7% for the average covered drug. Using formularies for Medicare Advantage plans, which are subject to uniform, nationwide benefit design standards, and the formulary status of newly approved drugs that do not satisfy the EHB requirement, I reject the hypotheses that consumer demand or effects on plan entry can explain my results. Copyright © 2017 John Wiley & Sons, Ltd.


Subject(s)
Drug Utilization Review/statistics & numerical data , Formularies as Topic , Insurance Benefits , Insurance Coverage/statistics & numerical data , Patient Protection and Affordable Care Act , Prescription Drugs/supply & distribution , Drug Costs , Drug Utilization Review/economics , Humans , United States
15.
J Pharm Pract ; 30(3): 296-299, 2017 Jun.
Article in English | MEDLINE | ID: mdl-27044642

ABSTRACT

INTRODUCTION: The use of vancomycin is common among hospitalized children. We sought to evaluate the impact of prospective audit with real-time feedback on vancomycin use and pharmacy costs. METHODS: Vancomycin use was evaluated at Monroe Carell Jr Children's Hospital at Vanderbilt (MCJCHV) before and after the implementation of prospective audit with intervention and feedback to providers in 2012. Antibiotic use was compared to academic children's hospitals with established antimicrobial stewardship programs (ASPs). Two similar pediatric academic institutions without an ASP were used as nonintervention controls. Analysis of monthly days of antibiotic therapy (DoT) per 1000 patient-days was performed by interrupted time series analysis. RESULTS: Monthly vancomycin use decreased from 114 DoTs/1000 patient-days to 89 DoTs/1000 patient-days ( P < .0001). We did not find significant differences in the slope of change in vancomycin use between MCJCHV and institutions with ASPs either before or after the intervention ( P = .86 and P = .71, respectively). When compared to children's hospitals without ASPs, the use of vancomycin was significantly lower at MCJCHV ( P < .001). CONCLUSION: The use of vancomycin at academic children's hospitals with an ASP is declining. In our experience, prospective audit with real-time intervention and feedback to providers significantly reduced the use and costs associated with vancomycin.


Subject(s)
Anti-Bacterial Agents/economics , Anti-Bacterial Agents/therapeutic use , Child, Hospitalized , Drug Utilization Review/economics , Vancomycin/economics , Vancomycin/therapeutic use , Child , Drug Utilization Review/methods , Hospitals, Teaching/economics , Humans , Prospective Studies
16.
Braz J Infect Dis ; 20(6): 631-634, 2016.
Article in English | MEDLINE | ID: mdl-27609214

ABSTRACT

Drug shortages pose a clear detriment to antimicrobial stewardship (AS) efforts. Our objective was to evaluate the effect of a piperacillin-tazobactam shortage on meropenem use, related costs, and associated changes in AS activity. A quasi-experimental quality improvement review compared adult patients receiving meropenem ≥72h three months pre-shortage and three months during the shortage. 320 patients were included (pre-shortage: 103; shortage: 217). Baseline characteristics were similar, but the length of stay was slightly longer in pre-shortage [19 (11-32) days] versus shortage [16 (11-32) days] (p=0.094). In pre-shortage and shortage, median days of therapy and estimated meropenem cost were 7 (5-11) and 7 (5-10) and $309.93 ($173.60-$507.03) and $255.30 ($204.24-$424.31), respectively (p=0.411 and p=0.050). Frequency of ID consultation was similar (16.8% in pre- and 25.3% in shortage, p=0.091). AS interventions increased during the shortage period (99 in pre-shortage and 205 in shortage). De-escalation occurred in 19.4% versus 32.7% of the patients in pre-shortage and shortage (p=0.014). The piperacillin-tazobactam shortage was associated with a 111% increase in meropenem prescriptions despite active AS, but was not associated with changes in mortality, length of therapy, or meropenem costs. AS should be aware that shortages may require proactive countermeasures to avoid inappropriate antimicrobial use during shortage periods.


Subject(s)
Anti-Bacterial Agents/administration & dosage , Drug Utilization Review/statistics & numerical data , Penicillanic Acid/analogs & derivatives , Thienamycins/administration & dosage , Adult , Aged , Anti-Bacterial Agents/economics , Drug Prescriptions/economics , Drug Prescriptions/statistics & numerical data , Drug Utilization Review/economics , Female , Hospital Mortality , Humans , Length of Stay , Male , Meropenem , Middle Aged , Penicillanic Acid/economics , Penicillanic Acid/supply & distribution , Piperacillin/economics , Piperacillin/supply & distribution , Piperacillin, Tazobactam Drug Combination , Thienamycins/economics
17.
Br J Clin Pharmacol ; 82(3): 831-8, 2016 09.
Article in English | MEDLINE | ID: mdl-27195696

ABSTRACT

AIMS: The aims were to assess the impact of a medication review with follow-up (MRF) service provided in community pharmacy to aged polypharmacy patients on the number of medication-related hospital admissions and to estimate the effect on hospital costs. METHODS: This was a sub-analysis of a cluster randomized controlled trials carried out in 178 community pharmacies in Spain. Pharmacies in the intervention group (IG) provided a comprehensive medication review during 6 months. Pharmacists in the comparison group (CG) delivered usual care. For the purposes of this sub-analysis, an expert panel of three internal medicine specialists screened the hospitalizations occurring during the main study, in order to identify medication-related hospitalizations. Inter-rater reliability was measured using Fleiss's kappa. Hospital costs were calculated using diagnosis related groups. RESULTS: One thousand four hundred and three patients were included in the main study and they had 83 hospitalizations. Forty-two hospitalizations (50.6%) were medicine-related, with a substantial level of agreement among the experts (kappa = 0.65, 95% CI 0.52, 0.78, P < 0.01). The number of medication-related hospitalizations was significantly lower in patients receiving MRF (IG 11, GC 31, P = 0.042). The probability of being hospitalized was 3.7 times higher in the CG (odds ratio 3.7, 95% CI 1.2, 11.3, P = 0.021). Costs for a medicine-related hospitalization were €6672. Medication-related hospitalization costs were lower for patients receiving MRF [IG: €94 (SD 917); CG: €301 (SD 2102); 95% CI 35.9, 378.0, P = 0.018]. CONCLUSION: MRF provided by community pharmacists might be an effective strategy to balance the assurance of the benefit from medications and the avoidance of medication-related hospitalizations in aged patients using polypharmacy.


Subject(s)
Community Pharmacy Services/economics , Drug Utilization Review/economics , Hospitalization/statistics & numerical data , Polypharmacy , Aged , Female , Health Care Costs/statistics & numerical data , Humans , Male , Observer Variation , Spain
18.
BMC Health Serv Res ; 16: 15, 2016 Jan 15.
Article in English | MEDLINE | ID: mdl-26772962

ABSTRACT

BACKGROUND: Medicaid programs face growing pressure to control spending. Despite evidence of clinical harms, states continue to impose policies limiting the number of reimbursable prescriptions (caps). We examined the recent use of prescription caps by Medicaid programs and the impact of policy implementation on prescription utilization. METHODS: We identified Medicaid cap policies from 2001-2010. We classified caps as applying to all prescriptions (overall caps) or only branded prescriptions (brand caps). Using state-level, aggregate prescription data, we developed interrupted time-series analyses to evaluate the impact of implementing overall caps and brand caps in a subset of states with data available before and after cap initiation. For overall caps, we examined the use of essential medications, which were classified as preventive or as providing symptomatic benefit. For brand caps, we examined the use of all branded drugs as well as branded and generic medications among classes with available generic replacements. RESULTS: The number of states with caps increased from 12 in 2001 to 20 in 2010. Overall cap implementation (n = 3) led to a 0.52% (p < 0.001) annual decrease in the proportion of essential prescriptions but no change in cost. For preventive essential medications, overall caps led to a 1.12% (p = 0.001) annual decrease in prescriptions (246,000 prescriptions annually) and a 1.20% (p < 0.001) decrease in spending (-$12.2 million annually), but no decrease in symptomatic essential medication use. Brand cap implementation (n = 6) led to an immediate 2.29% (p = 0.16) decrease in branded prescriptions and 1.26% (p = 0.025) decrease in spending. For medication classes with generic replacements, the decrease in branded prescriptions (0.74%, p = 0.003) approximately equaled the increase in generics (0.79%, p = 0.009), with estimated savings of $17.4 million. CONCLUSIONS: An increasing number of states are using prescription caps, with mixed results. Overall caps decreased the use of preventive but not symptomatic essential medications, suggesting that patients assign higher priority to agents providing symptomatic benefit when faced with reimbursement limits. Among medications with generic replacements, brand caps shifted usage from branded drugs to generics, with considerable savings. Future research should analyze the patient-level impact of these policies to measure clinical outcomes associated with these changes.


Subject(s)
Medicaid/economics , Prescription Drugs/economics , Drug Costs/trends , Drug Prescriptions/economics , Drug Utilization Review/economics , Drugs, Generic/economics , Health Policy/economics , Humans , Interrupted Time Series Analysis , United States
19.
Singapore Med J ; 56(9): 493-501, 2015 Sep.
Article in English | MEDLINE | ID: mdl-26451051

ABSTRACT

INTRODUCTION: There is a high prevalence of polypharmacy and inappropriate medication use in Singapore nursing homes. This study primarily explored the benefits of pharmacist reviews in local nursing homes. The secondary aims were to review the potential cost savings gained from following the pharmacists' recommendations and to identify the possible risks associated with polypharmacy and inappropriate medication use. METHODS: A retrospective period prevalence study was performed. We analysed the pharmacotherapy problems highlighted by pharmacists in three nursing homes and the rate of acceptance of pharmacists' recommendations. Data was collected in two phases: (a) a one-month pre-setup period, during which 480 patients were reviewed (i.e. one-time review before weekly pharmacist visits); and (b) a six-month post-setup period, during which the 480 patients were reviewed again. Pharmacotherapy problems were classified according to a clinical pharmacist recommendation taxonomy and potential risks were identified. Monthly cost savings were calculated and compared with the monthly costs of pharmacist reviews. RESULTS: A total of 392 pharmacotherapy problems were identified, with pharmacist recommendations noted for each problem. Among the 392 recommendations, 236 (60.2%) were accepted. The pharmacotherapy problems were analysed for potential risks, including falls (16.0%) and constipation (13.1%). The acceptance rates were higher during the post-setup period compared to the pre-setup period (p < 0.0001). Total direct acquisition cost savings during the pre- and post-setup periods were SGD 388.30 and SGD 876.69, respectively. CONCLUSION: The provision of pharmaceutical care to nursing home residents resulted in improved medication safety and quality of care.


Subject(s)
Drug Utilization Review/statistics & numerical data , Inappropriate Prescribing/statistics & numerical data , Nursing Homes , Polypharmacy , Aged , Drug Costs , Drug Utilization Review/economics , Female , Health Care Costs , Humans , Inappropriate Prescribing/economics , Male , Pharmaceutical Services/economics , Pharmacists , Prevalence , Retrospective Studies , Risk , Singapore
20.
J Manag Care Spec Pharm ; 21(4): 269-75, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25803760

ABSTRACT

BACKGROUND: Value-based insurance design attempts to align drug copayment tier with value rather than cost. Previous implementations of value-based insurance design have lowered copayments for drugs indicated for select "high value" conditions and have found modest improvements in medication adherence. However, these implementations have generally not resulted in cost savings to the health plan, suggesting a need for increased copayments for "low value" drugs. Further, previous implementations have assigned equal copayment reductions to all drugs within a therapeutic area without assessing the value of individual drugs. Aligning the individual drug's copayment to its specific value may yield greater clinical and economic benefits. In 2010, Premera Blue Cross, a large not-for-profit health plan in the Pacific Northwest, implemented a value-based drug formulary (VBF) that explicitly uses cost-effectiveness analyses after safety and efficacy reviews to estimate the value of each individual drug. Concurrently, Premera increased copayments for existing tiers. OBJECTIVE: To describe and evaluate the design, implementation, and first-year outcomes of the VBF. METHODS: We compared observed pharmacy cost per member per month in the year following the VBF implementation with 2 comparator groups: (1) observed pharmacy costs in the year prior to implementation, and (2) expected costs if no changes were made to the pharmacy benefits. Expected costs were generated by applying autoregressive integrated moving averages to pharmacy costs over the previous 36 months. We used an interrupted time series analysis to assess drug use and adherence among individuals with diabetes, hypertension, or dyslipidemia compared with a group of members in plans that did not implement a VBF.  RESULTS: Pharmacy costs decreased by 3% compared with the 12 months prior and 11% compared with expected costs. There was no significant decline in medication use or adherence to treatments for patients with diabetes, hypertension, or dyslipidemia. CONCLUSIONS: The VBF and copayment changes enabled pharmacy plan cost savings without negatively affecting utilization in key disease states.


Subject(s)
Chemistry, Pharmaceutical/economics , Cost-Benefit Analysis , Drug Costs , Drug Utilization Review/economics , Insurance, Pharmaceutical Services/economics , Value-Based Purchasing/economics , Blue Cross Blue Shield Insurance Plans/economics , Chemistry, Pharmaceutical/methods , Cost-Benefit Analysis/methods , Drug Costs/trends , Drug Utilization Review/methods , Drug Utilization Review/trends , Humans , Insurance, Pharmaceutical Services/trends , Value-Based Purchasing/trends
SELECTION OF CITATIONS
SEARCH DETAIL
...